Navigation Links
Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Date:12/10/2008

SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commencement of patient dosing for a Phase 1 clinical trial for a bisphosphonate administered with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) injection. This study will explore the safety, tolerability and pharmacokinetics of SC administration of a bisphosphonate plus rHuPH20. Currently, injectable bisphosphonates must be administered intravenously (IV).

"We are pleased that the first clinical trial is underway for our bisphosphonate program, our third proprietary product development initiative to enter clinical studies," stated Jonathan Lim, M.D., President and CEO of Halozyme Therapeutics. "The bisphosphonate program joins insulin, for diabetes, and Chemophase, for superficial bladder cancer, our other two proprietary programs in clinical development. The goal of Halozyme's bisphosphonate program is to provide an alternative dosage formulation that may offer greater convenience, compliance and tolerability to patients for the treatment of osteoporosis."

This Phase 1 dose ranging clinical trial will assess the safety, tolerability and pharmacokinetics of a bisphosphonate with and without co-administration of rHuPH20 across a range of bisphosphonate concentrations and volumes and various rHuPH20 doses. The study will also compare SC administration of a bisphosphonate plus rHuPH20 to IV bisphosphonate alone.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for t
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
2. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
5. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
8. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
9. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Today DePuy Synthes Companies of Johnson ... systems featuring its proprietary variable angle locking technology. ... to match patient anatomy and fracture pattern and ... systems are being introduced in conjunction with the ... the International Federation of Foot & Ankle Societies ...
(Date:9/19/2014)... VIEW, Calif. , Sept. 19, 2014 Today, ... in capital from Xiaomi Ventures, Ltd. for its first ... used to continue expanding iHealth,s global reach, accelerate growth ... resources.  As part of the investment, Xiaomi Ventures will ... the areas of cloud infrastructure and ecommerce. ...
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... Cargill today announced encouraging preliminary results from its ... head of beef cattle.  Initial results are based upon ... company,s Fort Morgan, Colo., beef processing facility where vaccinated ... Addressing the food and feed safety ...
... Nov. 15, 2010 Breathe Technologies, manufacturer of devices ... has appointed Lawrence A. Mastrovich as the new President ... us a phenomenal wealth of experience and strategic guidance," ... visible and instrumental role in building value within the ...
Cached Medicine Technology:Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 2Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 3Breathe Technologies Appoints New CEO 2
(Date:9/21/2014)... While public health authorities focus on the physical activity ... University of Montreal reveals that for children, playing has ... an activity that is fun, done alone or with ... or pleasure, but also to combat boredom, sadness, fear, ... of play, authorities put aside several aspects of play ...
(Date:9/21/2014)... PhUSE is proud to announce Dr. Pritpal ... keynote speakers for their 10th annual conference which is ... Goldacre in 2013 , Charles Sabine in 2012 ... PhUSE again presents high-calibre speakers to talk about relevant ... clinical information. , Dr. Pritpal Tamber is a "health ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... New York, NY (PRWEB) September 21, 2014 ... has enabled more generic drugs to inundate the market, ... Name Pharmaceutical Manufacturing industry. According to data from ... drugs has cost the industry $1.8 and $2.5 billion ... blockbuster, brand-name drugs losing patent exclusivity, which has hampered ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3
... demonstrated that our own experience is important to exhibit feelings ... been working hard to understand what happens in our brain ... The results of the observation show that the actions of ... ,The research points out that we understand the actions ...
... Reports from World Health Organization (WHO), shows that 36 million ... heart diseases, stroke, cancer and diabetes and serious measures has ... 10 years. The main factors which are responsible for the ... exercise, people eating more food rich in fats and sugars, ...
... as it is commonly known is a silent killer because ... disease. However, it can lead to a lot of complications ... left untreated. Fortunately, it can be diagnosed by a very ... anti-hypertensive medication., ,Two inexpensive, but widely overlooked drugs may ...
... the dilemmas of geographical separation between the doctor and ... the feasibility of telephone consultation as an alternative method ... for busy patients and may save costs. Telemedicine has ... medical information and services., ,Successful communication is based ...
... One of the biggest challenges in the delivery of ... primary health centres (PHCs) and community health centres (CHCs) ... lack of basic amenities and incentives. An important reason ... of accountability in our public health services. While the ...
... Human papillomavirus (HPV) is one of the most common causes ... 100 different types of HPV exist, most of which are ... // membranes, causing warts to grow in the anal, genital, ... or venereal warts are the most easily recognized sign of ...
Cached Medicine News:Health News:Feelings Of Sympathy And Empathy Dictated by Personal Experience 2Health News:Feelings Of Sympathy And Empathy Dictated by Personal Experience 3Health News:Common, cheaper drugs could be used to treat hypertension 2Health News:Medical Mishaps In Telemedicine And Their Prevention 2Health News:Problems in rural health delivery and remedies 2
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
Medicine Products: